Core Viewpoint - Guizhou BaiLing (ST BaiLing) has completed internal control rectification and is applying to remove the risk warning label after a year of efforts, aiming for a turnaround in its financial performance [2][6]. Internal Control and Compliance - The company has made significant improvements in its internal control and compliance systems, establishing a compliance management department and enhancing training for staff to prevent future violations [5][6]. - An audit report confirmed that ST BaiLing maintained effective internal control over financial reporting in all significant aspects [6]. Financial Performance - In 2024, ST BaiLing reported revenue of 3.825 billion yuan, a decrease of 10.26% year-on-year, while net profit attributable to shareholders was 33.62 million yuan, an increase of 108.11% [7]. - Despite appearing to turn a profit, the company's net profit after excluding non-recurring items was -82.44 million yuan, indicating ongoing financial challenges [7]. Market Challenges - The company faced declining demand for its products due to a public health event in late 2023, which led to overstocking of certain medications, resulting in reduced sales in 2024 [7][8]. - In the first quarter of 2025, revenue dropped to 761 million yuan, a decline of 42.93% year-on-year, with a significant decrease in net profit [7][8]. Accounts Receivable and Risk Management - As of the end of the first quarter of 2025, ST BaiLing's accounts receivable reached 1.843 billion yuan, a 15.51% increase from the beginning of the year [8]. - The company is actively managing credit risks by conducting assessments of customers and monitoring receivables to mitigate potential bad debt risks [8].

Group 1 - The company's stock (ST Bailin, code: 002424) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 12% over two consecutive trading days (June 19 and June 20, 2025) [1] - The company's board confirmed that there were no corrections or supplements needed for previously disclosed information, and no significant undisclosed information that could impact stock prices was found [1][2] - The company's operational situation and external environment have not undergone significant changes, and there are no undisclosed major matters related to the company during the period of stock fluctuation [1][2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's listing rules, nor any significant information that could impact the company's stock and derivatives trading prices [2] - The company has conducted a self-examination and found no violations of fair information disclosure [3]

证券代码：002424 证券简称：ST 百灵 公告编号：2025-031 贵州百灵企业集团制药股份有限公司（以下简称"公司"或"本 公司"）股票（证券简称：ST 百灵，证券代码：002424）连续 2 个交 易日（2025 年 6 月 19 日、2025 年 6 月 20 日）日收盘价格涨幅偏离 值累计超过 12%，根据深圳证券交易所的有关规定，属于股票交易异 常波动的情况。 二、公司关注及核实情况的说明 贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 针对公司股票交易异常波动，公司董事会对公司、控股股东及实 际控制人就相关事项进行了核实，现就有关情况说明如下： 1、公司未发现前期披露的信息存在需要更正、补充之处； 2、公司未发现近期公共传媒报道可能或已对公司股票交易价格 产生较大影响的未公开重大信息； 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的 应披露而未披露的重大事项，或处于筹划阶段的重大事项，股票异 ...

Core Viewpoint - ST Bailin (SZ002424) has applied to the Shenzhen Stock Exchange to lift its risk warning after rectifying internal control deficiencies identified in its 2023 audit report, which received a negative opinion from its accounting firm [1][2]. Group 1: Internal Control Issues - The negative opinion from the accounting firm was due to significant deficiencies in internal controls related to sales expenses, leading to failures in financial reporting [1][3]. - The Guizhou Securities Regulatory Bureau found two main issues: inaccurate accounting treatment of sales expenses and significant internal control deficiencies, resulting in the company’s financial data being untruthful for several years [4]. Group 2: Financial Performance and Adjustments - ST Bailin revised multiple data points in its 2023 annual report, and its sales expenses reached 2.311 billion yuan, an increase of 780 million yuan or 51% year-on-year [3]. - The company reported a net profit of 33.62 million yuan for the previous year, largely due to non-recurring gains, including government subsidies of 47.0556 million yuan [5]. Group 3: Ongoing Investigations and Future Outlook - The China Securities Regulatory Commission is still investigating ST Bailin for suspected information disclosure violations, with no conclusion reached as of May [5][6]. - The company’s first-quarter performance in 2024 showed a significant decline, with revenue down over 40% and net profit down over 50% year-on-year, indicating ongoing challenges in its financial health [6].

Core Viewpoint - Guizhou Bailing Pharmaceutical Group Co., Ltd. (ST Bailing) has applied to revoke its other risk warning status after completing internal control rectifications and ensuring effective operation of its internal controls, meeting the requirements for revocation [1][3] Group 1: Company Actions and Financial Performance - The company has implemented a series of internal control and compliance measures to address previous deficiencies, including the establishment of a compliance management department and hiring third-party consultants for technical support [2][3] - In 2024, ST Bailing achieved operating revenue of 3.825 billion yuan, a decrease of 10.26% compared to 4.263 billion yuan in 2023, while the net profit attributable to shareholders was 33.62 million yuan, marking a significant turnaround from a loss of 415 million yuan in 2023 [4][5] - Despite improvements, the company's non-recurring net profit remained negative at -82.44 million yuan, although this represented an 81.33% reduction in losses compared to the previous year [5] Group 2: Regulatory Background and Compliance Issues - The company was placed under other risk warning status in May 2024 due to a non-standard audit opinion from Tianjian Accounting Firm, which identified significant internal control deficiencies related to sales expense recognition [4] - Prior regulatory inspections revealed multiple issues, including delayed accounting for sales expenses and inaccuracies in financial reporting for 2021 and 2022, leading to administrative measures from the Guizhou Securities Regulatory Bureau [4]

Meeting Details - The sixth board meeting of Guizhou Bailing Pharmaceutical Group Co., Ltd. was convened by Chairman Jiang Wei on June 18, 2025 [2][3] - The meeting was held at the company's conference room with all 9 board members present, including independent directors participating via communication [3][4] Resolutions Passed - The board approved the proposal to apply for the removal of other risk warnings, with a unanimous vote of 9 in favor [6][9] - The board also approved a proposal for the company to provide a guarantee for its subsidiary, Anshun Dajiankang Pharmaceutical Industry Operation Co., Ltd., for a loan of 148 million yuan, with the company guaranteeing 81.4 million yuan [7][9] - A proposal to convene the second extraordinary general meeting of shareholders in 2025 was also approved unanimously [10][11] Guarantee Details - The subsidiary intends to apply for a loan of 148 million yuan from Guizhou Bank for a term of 2 years, with the company providing a guarantee based on its 55% ownership [15][21] - The total amount of guarantees provided by the company and its subsidiaries will reach 213.4 million yuan, accounting for 6.71% of the company's latest audited net assets [23] Risk Warning Removal - The company was previously under risk warning due to a negative internal control audit report for 2023, which has since been rectified [25][26] - The company has implemented various measures to improve internal controls and has received a qualified audit report for 2024, indicating compliance with the requirements for removing the risk warning [28][29] Upcoming Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for July 4, 2025, with provisions for both on-site and online voting [31][32] - Shareholders must register by June 27, 2025, to participate in the meeting [35]

证券代码：002424 证券简称：ST百灵 公告编号：2025-028 贵州百灵企业集团制药股份有限公司 关于申请撤销其他风险警示的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 特别提示：关于贵州百灵企业集团制药股份有限公司（以下简称"公司"） 申请撤销对公司股票交易实施其他风险警示事项尚需深圳证券交易所批准同意， 存在不确定性，敬请广大投资者注意投资风险。 2024年度公司围绕"摘帽扭亏"核心任务，全体员工在董事会的 领导下，全力开展内控整改及质量专项提升工作，采取以下整改和提 升措施： （1）根据最新的法律法规及规范运作规则，结合《企业内部控 制基本规范》及配套指引的有关要求，公司全面梳理、完善内部制度； （2）在审计委员会的监督和指导下，加强内部审计部门的审计 监督职能。公司内部审计部门、财务部门和市场监管部门密切关注、 定期核查公司与经销商之间销售费用政策执行、费用结算、费用计提、 款项回收等方面工作，修订完善销售费用政策，规范市场费用票据报 销管理，完善年度销售费用统计确认等，明确职责并建立奖惩机制， 确保各部门严格执行流程，提升公司规范化 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2025-029 贵州百灵企业集团制药股份有限公司 关于对控股子公司提供担保的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 特别提示： 本公司对安顺市大健康医药产业运营有限公司（资产负债率 85.79%）的担保金额为 10,890 万元,占公司最近一期经审计净资产的 比例为 3.42%。请投资者充分关注担保风险。 一、担保事项概述 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）控 股子公司安顺市大健康医药产业运营有限公司（以下简称"大健康医 药"）原向贵州银行股份有限公司安顺分行申请的贷款 14,800 万元即 将到期，为保障其资金正常运转，大健康医药拟向贵州银行股份有限 公司安顺分行申请续贷款 14,800 万元，期限为 2 年，公司将继续按 持股比例 55%提供连带责任担保 8,140 万元，大健康医药另一股东安 顺市医投科技服务有限公司将按持股比例 45%提供连带责任担保 6,660 万元。 2、董事会审议情况 申请贷款提供担保的议案》，本议案需提交股东大会审议。 3、根据《深圳 ...

证券代码：002424 证券简称：ST百灵 公告编号：2025-030 贵州百灵企业集团制药股份有限公司 关于召开 2025 年第二次临时股东会通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）将于2025年7月4 日召开2025年第二次临时股东会，现将本次会议的有关事项通知如下： 一、召开会议的基本情况： （一）股东会届次：2025年第二次临时股东会 （二）股东会召集人：本次股东会由董事会召集，《关于召开2025年第二次 临时股东会的议案》已经公司第六届董事会第十七次会议审议通过。 （三）会议召开的合法、合规性：本次股东会的召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》等的规定。 （四）现场会议召开的日期、时间及网络投票时间： 1、现场会议召开的日期、时间：2025年7月4日（星期五）上午十时 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为2025年7月4日（现场股东会召开当日）的交易时间，即9:15—9:25,9:30—11:30 和13:00—15: ...

证券代码：002424 证券简称：ST百灵 公告编号：2025-027 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十七次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 2、本次董事会于2025年6月18日上午10:00在公司三楼会议室以 现场结合通讯方式召开。 3、本次董事会应参会表决董事共9人，实际参会表决的董事9人。 其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持，公司监事和高级管理人 员列席了本次董事会。 5、本次董事会的召集、召开符合《公司法》《公司章程》《董事 会议事规则》及相关法规的规定。 二、会议审议情况 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《关于申请撤销其他风险警示的议案》； 具 体 内 容 详 见 公 司 在 指 定 信 息 披 露 媒 体 巨 潮 资 讯 网 （www.cninfo.com.cn）、《证券时报》《证券日报》《中国证券报》 《上海证券报》披露的《关于申请撤销其他风险警示的公告》。 一、会议召开情况 1、贵州百灵企业集团制药股 ...